Prognostic Stage IIIA Breast Cancer AJCC v8

Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon

A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.


Localized Breast Carcinoma

Breast carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Invasive Breast Cribriform Carcinoma

An invasive adenocarcinoma of the breast with a favorable clinical outcome, characterized by the presence of a sieve-like or cribriform infiltrating pattern.


Intraductal Micropapillary Breast Carcinoma

Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.


Solid papillary carcinoma in situ of breast

Breast solid papillary carcinoma characterized by the presence of nodules with rounded, well-circumscribed contours and a distribution pattern consistent with an in situ process. (WHO 2019)


Stage IIA Breast Carcinoma

Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Stage IIIC Breast Cancer AJCC v7

Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Recurrent Hormone Receptor-Negative Breast Carcinoma

The reemergence of hormone receptor-negative breast carcinoma after a period of remission.


breast angiosarcoma

A malignant vascular neoplasm arising from the breast.


Invasive Breast Lobular Carcinoma, Solid Variant

A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.


Metastatic Triple-Negative Breast Carcinoma

A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Invasive Breast Lobular Carcinoma with Predominant In Situ Component

A breast carcinoma characterized by the presence of a predominant lobular carcinoma in situ component and a minor component of invasive carcinoma.


Recurrent Malignant Breast Neoplasm

The reemergence of a malignant breast neoplasm after a period of remission.


Invasive Breast Lobular Carcinoma, Alveolar Variant

A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.


Hereditary Female Breast Carcinoma

Breast carcinoma that has developed in female relatives of patients with history of breast carcinoma.


High Grade Ductal Breast Carcinoma In Situ

Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.


Breast Carcinoma Metastatic in the Liver

A carcinoma that originates from the breast and has spread to the liver.


Unresectable HER2-Negative Breast Carcinoma

HER2-negative breast carcinoma that is not amenable to surgical resection.


Histiocytoid Breast Carcinoma

A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.


Squamous Cell Carcinoma In Situ of the Nipple

An intraepidermal squamous cell carcinoma involving the area of the nipple.


malignant neoplasm of breast stage I

Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0).  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T0: No evidence of primary tumor.  N0: No regional lymph node metastasis.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Prognostic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Locally Recurrent Breast Carcinoma

The reemergence of breast carcinoma after a period of remission, at or adjacent to the site of the original tumor.


Refractory HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that is resistant to treatment.


Invasive Breast Solid Papillary Carcinoma

Breast solid papillary carcinoma associated with areas featuring strands or large clusters of tumor cells. (WHO 2019)


Breast Florid Lobular Carcinoma In Situ

Breast lobular carcinoma in situ characterized by the presence of neoplastic cells with cytological features identical to classic lobular carcinoma in situ, but with marked distention of terminal ductal lobular units or ducts.


adenocarcinoma of breast with neuroendocrine differentiation

An invasive breast carcinoma characterized by the presence of focal neuroendocrine differentiation.


Metastatic Breast Inflammatory Carcinoma

Inflammatory carcinoma of the breast that has spread from its original site of growth to another anatomic site.


Metastatic Breast Neuroendocrine Tumor G1

A well differentiated neuroendocrine tumor that arises from the breast and has metastasized to other anatomic sites.


Stage IV Breast Cancer AJCC v6 and v7

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)


Unresectable Hormone Receptor-Negative Breast Carcinoma

Hormone receptor-negative breast carcinoma that is not amenable to surgical resection.


Breast Classic Lobular Carcinoma In Situ

Breast lobular carcinoma in situ characterized by the presence of dyscohesive proliferations of type A and/or type B epithelial cells. Type A cells are small cells with uniform hyperchromatic nuclei, whereas type B cells have slightly larger vesicular nuclei, with mild variability in size and shape and with small nucleoli. The cell populations may be mixed in individual proliferations. (WHO 2019)


Atypical Medullary Breast Carcinoma

An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.


Refractory Hormone Receptor-Negative Breast Carcinoma

Hormone receptor-negative breast carcinoma that is resistant to treatment.


Breast Periductal Stromal Tumor

A rare, low-grade malignant stromal tumor that arises from the breast. It is characterized by the proliferation of atypical stromal spindle cells that surround benign tubules and ducts in a pericanalicular pattern. Mitotic activity is present. The tumor has a multinodular and infiltrative growth pattern and lacks the leaf-like architecture of phyllodes tumor. Wide excision with negative margins is the treatment of choice.


Primary angiosarcoma of breast

An angiosarcoma that arises from the breast parenchyma and is not associated with radiation exposure.


Metastatic HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that has spread to another anatomic site.


Recurrent HER2-Positive Breast Carcinoma

The reemergence of HER2-positive breast carcinoma after a period of remission.


Anatomic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Stage IIIC Breast Cancer AJCC v6

Stage IIIC Breast Cancer was added in the 6th Edition AJCC Staging Manual, on the basis of metastasis to the infraclavicular lymph nodes (N3) plus any T, M0.


Hormone Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for hormone receptors.


Refractory Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.


breast leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, arising from the breast. It is characterized by a proliferation of neoplastic spindle cells.


Malignant nipple neoplasm male

A malignant neoplasm that affects the area of the nipple in males.


Metastatic Breast Neuroendocrine Neoplasm

A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.


Inflammatory carcinoma of breast stage III

Inflammatory breast carcinoma is classified as AJCC Stage IIIB (T4d) unless other criteria indicate more advanced staging.


High Grade Breast Mucoepidermoid Carcinoma

An aggressive mucoepidermoid carcinoma characterized by the presence of focal necrosis and high mitotic activity.  Lymph node and distant metastases are common.  The prognosis is usually poor.


Postradiation Breast Angiosarcoma

A malignant vascular neoplasm arising from the skin of the breast secondary to radiation treatment for breast cancer.


Progesterone Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for progesterone receptors.


Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma

An invasive ductal breast carcinoma associated with an invasive lobular carcinomatous component.


Metastatic Estrogen Receptor-Positive Breast Carcinoma

Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Multicentric Breast Carcinoma

A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.


Breast Cancer by AJCC v8 Prognostic Stage

A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)


Stage IIIB Breast Carcinoma

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Locally Advanced HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Prognostic Stage IIB Breast Cancer AJCC v8

Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Male Breast Carcinoma

A rare invasive carcinoma that arises from the male breast. Morphologically, it is similar to the invasive carcinomas that arise from the female breast. It usually develops in the retroareolar region.


Anatomic Stage II Breast Cancer AJCC v8

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Low Grade Breast Adenosquamous Carcinoma

A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.


Refractory Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that is resistant to treatment.


Noninfiltrating intraductal papillary adenocarcinoma (morphologic abnormality)

Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)


HER2-Low Breast Carcinoma

Breast adenocarcinoma defined by low expression of HER2 (IHC1+ or IHC2+; FISH negative).


Metastatic Breast Signet Ring Cell Carcinoma

A signet ring cell carcinoma that arises from the breast and has metastasized to other anatomic sites.


Breast adenocarcinoma metastatic

An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.


Recurrent Estrogen Receptor-Positive Breast Carcinoma

The reemergence of estrogen receptor-positive breast carcinoma after a period of remission.


Stage II Breast Cancer AJCC v6 and v7

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Inflammatory carcinoma of breast recurrent

The reemergence of inflammatory carcinoma of the breast after a period of remission


Breast Carcinoma with Choriocarcinomatous Features

An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.


Prognostic Stage II Breast Cancer AJCC v8

Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Carcinoma in situ of female breast

A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the female breast.


Intraductal papillary adenocarcinoma with invasion

A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.


Recurrent Breast Angiosarcoma

The reemergence of breast angiosarcoma after a period of remission.


Anatomic Stage IIA Breast Cancer AJCC v8

Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Malignant neoplasm of nipple of female breast

A malignant neoplasm that affects the area of the nipple in females.


Paget's disease and infiltrating duct carcinoma of breast

Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Anatomic Stage IA Breast Cancer AJCC v8

Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Breast Lobular Carcinoma, Tubulolobular Variant

An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.


Hormone Receptor-Negative Breast Carcinoma

Breast adenocarcinoma that is negative for hormone receptors.


Locally Advanced Estrogen Receptor-Positive Breast Carcinoma

Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Breast sarcoma recurrent

The reemergence of breast sarcoma after a period of remission.


Breast Carcinoma with Osseous Metaplasia

An invasive breast carcinoma showing differentiation towards bone structures.


Breast Polymorphous Adenocarcinoma

A rare, low grade malignant epithelial neoplasm arising from the breast. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern.


Stage III Breast Cancer AJCC v7

Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


BRCA-Associated Breast Carcinoma

Breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


Unresectable Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast carcinoma that is not amenable to surgical resection.


Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component

An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.


Prognostic Stage IA Breast Cancer AJCC v8

Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Pleomorphic lobular carcinoma in situ of breast

Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.


Invasive micropapillary carcinoma of breast

An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.


Anatomic Stage IIIB Breast Cancer AJCC v8

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Unilateral Breast Carcinoma

Breast carcinoma of one breast, or one side of the breast.


Childhood Malignant Breast Neoplasm

A malignant neoplasm that affects the breast and occurs during childhood.


Carcinoma in situ of male breast

A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the male breast. It includes the entire spectrum of carcinoma in situ observed in the female breast. It usually develops in the retroareolar region.


Paget's disease and intraductal carcinoma of breast

Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.


Stage III Breast Cancer AJCC v6

Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Metastatic Breast Lobular Carcinoma

A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Breast Adenocarcinoma

Breast adenocarcinoma that does not respond to treatment.


Invasive Breast Carcinoma by Histologic Grade


Unresectable Breast Carcinoma

Breast carcinoma that is not amenable to surgical resection.


Recurrent HER2-Negative Breast Carcinoma

The reemergence of HER2-negative breast adenocarcinoma after a period of remission.


Breast adenocarcinoma recurrent

The reemergence of breast adenocarcinoma after a period of remission.


PALB2-Associated Breast Carcinoma

Breast carcinoma caused by deleterious germline mutation in the PALB2 gene.


Recurrent Invasive Breast Carcinoma of No Special Type

The reemergence of invasive breast carcinoma of no special type after a period of remission.


Metastatic Breast Carcinoma

A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Breast Lymphoma

Breast lymphoma that is resistant to treatment.


Malignant nipple neoplasm

A malignant neoplasm that affects the area of the nipple.


Breast Ductal Carcinoma In Situ, Comedo Type

Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.


Occult Breast Carcinoma

Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.


Prognostic Stage III Breast Cancer AJCC v8

Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


solid type ductal carcinoma in situ of breast

Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.


breast liposarcoma

A malignant adipose tissue neoplasm of the breast.


Prognostic Stage IV Breast Cancer AJCC v8

Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Metastatic Androgen Receptor-Positive Breast Carcinoma

Androgen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


breast sarcoma

A malignant mesenchymal neoplasm that arises from the breast. Representative examples include angiosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and extraskeletal osteosarcoma.


Breast Carcinoma Metastatic in the Lung

A carcinoma that arises from the breast and has metastasized to the lung.


Invasive Breast Apocrine Carcinoma

An invasive breast adenocarcinoma with cytological and immunophenotypic characteristics of apocrine differentiation in more than 90 percent of the malignant cells.


Anatomic Stage IIIC Breast Cancer AJCC v8

Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Prognostic Stage IIIC Breast Cancer AJCC v8

Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Triple-Negative Breast Inflammatory Carcinoma

Triple-negative breast inflammatory carcinoma that has spread from its original site of growth to another anatomic site.


Carcinoma breast stage I

Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003


Breast Tall Cell Carcinoma with Reversed Polarity

A rare subtype of invasive breast carcinoma characterized by tall columnar cells with reversed nuclear polarity, arranged in solid and solid papillary patterns, most commonly associated with IDH2 p.Arg172 hotspot mutations. (WHO 2019)


Androgen Receptor-Positive Breast Carcinoma

Breast carcinoma that is positive for androgen receptors.


Synchronous Ipsilateral Breast Carcinoma

Diagnosis of more than one distinct tumor focus in the same breast, within two months.


Anatomic Stage IIB Breast Cancer AJCC v8

Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Grade 1 Invasive Breast Carcinoma

A well differentiated invasive breast carcinoma.


Unresectable HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that is not amenable to surgical resection.


Secondary malignant neoplasm of breast

The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.


Grade 3 Invasive Breast Carcinoma

A poorly differentiated invasive breast carcinoma.


Unresectable Estrogen Receptor-Positive Breast Carcinoma

Estrogen receptor-positive breast carcinoma that is not amenable to surgical resection.


Stage IB Breast Cancer AJCC v7

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Breast Cancer by AJCC v7 Stage

A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 7th edition.


Stage IIB Breast Carcinoma

Stage IIB includes: (T2, N1, M0); (T3, N0, M0).  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Anatomic Stage IB Breast Cancer AJCC v8

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Ductal Carcinoma In Situ and Lobular Carcinoma

A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.


breast extraskeletal osteosarcoma

An osteosarcoma arising from the breast tissue.


Breast Ductal Carcinoma In Situ, Non-Comedo Type

Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells without evidence of central necrosis or cell death.


Locally Advanced Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Invasive Breast Lobular Carcinoma, Signet Ring Variant

An invasive lobular carcinoma characterized by the presence of malignant epithelial cells with large intracytoplasmic lumina that cause displacement of the nuclei towards one pole of the cells.


Prognostic Stage I Breast Cancer AJCC v8

Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IIIA Breast Cancer AJCC v8

Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Breast Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the breast parenchyma and has metastasized to other anatomic sites.


Invasive papillary breast carcinoma

An invasive breast carcinoma characterized by the presence of papillary structures.


adenocarcinoma of breast with spindle cell metaplasia

An invasive adenocarcinoma of the breast usually affecting post-menopausal women, characterized by extensive spindle cell metaplasia of the neoplastic glandular cells.


Recurrent Progesterone Receptor-Positive Breast Carcinoma

The reemergence of progesterone receptor-positive breast carcinoma after a period of remission.


Metastatic Breast Carcinoma in the Skin

A carcinoma that arises from the breast and has metastasized to the skin.


Anatomic Stage IV Breast Cancer AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Ductal Carcinoma In Situ with Microinvasion

Invasive breast carcinoma measuring 1 mm or less in size.


Early Stage Breast Carcinoma

Breast carcinoma that has not spread beyond the breast and the axillary lymph nodes.


Unresectable Breast Inflammatory Carcinoma

Inflammatory breast carcinoma that is not amenable to surgical resection.


Invasive Female Breast Carcinoma

An invasive carcinoma that arises from the breast in females.


Refractory HER2-Negative Breast Carcinoma

HER2-negative breast adenocarcinoma that is resistant to treatment.


Breast Carcinoma with Chondroid Metaplasia

An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.


Metastatic HER2-Low Breast Carcinoma

HER2-low breast adenocarcinoma that has spread from its original site of growth to another anatomic site.


malignant breast phyllodes tumor

A phyllodes tumor of the breast characterized by infiltrative margins and a sarcomatous stromal component. The sarcomatous stroma usually displays features of fibrosarcoma. Liposarcomatous, osteosarcomatous, or rhabdomyosarcomatous elements may also be present.


Hereditary Male Breast Carcinoma

Breast carcinoma that has developed in male relatives of patients with history of breast carcinoma.


Recurrent Breast Paget Disease

The reemergence of Paget disease of the breast after a period of remission.


Early Stage Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that has not spread beyond the breast or axillary lymph nodes.


Locally Advanced Breast Adenocarcinoma

Breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Childhood Breast Carcinoma

A rare breast carcinoma that occurs during childhood.


Breast Ductal Carcinoma with Squamous Metaplasia

An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the ductal carcinomatous component.


Metastatic Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Stage IA Breast Cancer AJCC v7

Stage IA includes: T1, N0, M0.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast lymphoma

A lymphoma that arises from the breast. There is no history of extramammary breast lymphoma and ipsilateral axillary lymph node involvement does not exclude the diagnosis of primary breast lymphoma. Most patients present with a painless breast lump. The vast majority of cases are B-cell non-Hodgkin lymphomas. Diffuse large B-cell lymphoma, follicular lymphoma, and extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue are the most common types of primary non-Hodgkin lymphoma of the breast. Primary Hodgkin lymphoma of the breast is rare.


Invasive Breast Lobular Carcinoma, Pleomorphic Variant

A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.


Breast Cancer by AJCC v8 Anatomic Stage

A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)


Breast cancer recurrent

The reemergence of carcinoma in the breast after a period of remission.


Breast Mixed Carcinoma

An invasive breast carcinoma characterized by the presence of more than one malignant epithelial histologic pattern.


Breast Carcinoma with Melanotic Features

A very rare primary malignant tumor of the breast, characterized by an invasive breast carcinoma that co-exists with a melanoma component.  The vast majority of melanotic tumors that affect the breast are metastatic melanomas that originate in extra-mammary sites.


Breast Paget Disease without Invasive Carcinoma

Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.


Refractory Breast Carcinoma

Breast carcinoma that does not respond to treatment.


Breast Cancer by AJCC v8 Stage

A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)


Breast Classic Lobular Carcinoma In Situ Type A

Breast classic lobular carcinoma in situ characterized by the presence of neoplastic cells with uniform nuclei.


Unresectable Triple-Negative Breast Carcinoma

Triple-negative breast carcinoma that is not amenable to surgical resection.


Advanced Breast Carcinoma

Breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Inflammatory carcinoma of breast stage IV

An inflammatory carcinoma of the breast that has spread to other anatomic sites.


Metastatic HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that has spread from the original site of growth to another anatomic site.


Prognostic Stage IIIB Breast Cancer AJCC v8

Stage IIIB includes: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Cancer by AJCC v6 Stage

A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 6th edition.


Recurrent Breast Lymphoma

The reemergence of breast lymphoma after a period of remission.


Breast Ductal Carcinoma In Situ, Low Grade

Breast ductal carcinoma in situ characterized by the presence of small, monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. The nuclei are uniform and mitotic figures are rare.


Locally Advanced Breast Carcinoma

A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Contralateral Breast Carcinoma

Breast carcinoma that develops in the opposite breast of a patient with an already diagnosed primary breast carcinoma.


Prognostic Stage IB Breast Cancer AJCC v8

Stage IB includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Squamous Cell Carcinoma in the Breast

A squamous cell carcinoma that has spread to the breast from another anatomic site.


malignant breast melanoma

A melanoma that arises usually from the breast skin and less often from the breast glandular tissue. Primary breast melanomas are rare.


Prognostic Stage IIA Breast Cancer AJCC v8

Stage IIA includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Oligometastatic Breast Carcinoma

Breast carcinoma that has metastasized to a limited number of sites.


Encapsulated Breast Papillary Carcinoma

Breast carcinoma characterized by the presence of fine fibrovascular stalks covered by neoplastic epithelial cells of low or intermediate nuclear grade, typically present within a cystic space and surrounded by a fibrous capsule. There are usually no myoepithelial cells along the papillae or at the periphery of the lesion. (WHO 2019)


Breast Carcinoma Metastatic in the Brain

A carcinoma that has spread to the brain from its original site in the breast, through the hematogenous route.


Encapsulated Breast Papillary Carcinoma with Invasion

Encapsulated breast papillary carcinoma characterized by the presence of neoplastic elements that permeate beyond the fibrous capsule with an irregular infiltrative appearance. (WHO 2019)


Breast Carcinoma with Osteoclast-Like Stromal Giant Cells

An invasive breast adenocarcinoma characterised by the presence of non-neoplastic stromal osteoclastic giant cells.  The carcinomatous component is usually an invasive ductal carcinoma, although all other breast adenocarcinoma subtypes have also been described.  The prognosis depends on the characteristics of the adenocarcinomatous component, and is not related to the presence of the giant cells.


Grade 2 Invasive Breast Carcinoma

A moderately differentiated invasive breast carcinoma.


Anatomic Stage III Breast Cancer AJCC v8

Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage I Breast Cancer AJCC v8

Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Malignant Breast Neoplasm

A malignant breast neoplasm that has metastasized to another anatomic site.


Resectable Breast Carcinoma

Breast carcinoma that is amenable to surgical resection.


Low Grade Breast Mucoepidermoid Carcinoma

A slow growing mucoepidermoid carcinoma characterized by the presence of keratinization in the neoplastic squamous cells and lumina formation by glandular neoplastic cells.  Complete excision may be curative.


Metastatic BRCA-Associated Breast Carcinoma

BRCA-associated breast carcinoma that has spread to another anatomic site.


Recurrent Lobular Breast Carcinoma

The reemergence of lobular breast carcinoma after a period of remission.


Estrogen Receptor-Positive Breast Carcinoma

Breast adenocarcinoma that is positive for estrogen receptors.


Invasive Breast Lobular Carcinoma with Extracellular Mucin

A rare variant of invasive breast lobular carcinoma characterized by the presence of pools of extracellular mucin in which groups of floating lobular carcinoma cells are identified.


Breast Ductal Carcinoma In Situ, Intermediate Grade

Breast ductal carcinoma in situ characterized by the presence of monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. Intraluminal necrosis is present in some ducts. Ducts that contain neoplastic cells with occasional nucleoli and coarse chromatin may also be present.


Recurrent Hormone Receptor-Positive Breast Carcinoma

The reemergence of hormone receptor-positive breast adenocarcinoma after a period of remission.


adenocarcinoma of breast with squamous metaplasia

An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the adenocarcinoma component.


Recurrent Triple-Negative Breast Carcinoma

The reemergence of triple-negative breast carcinoma after a period of remission.


Metastatic Progesterone Receptor-Positive Breast Carcinoma

Progesterone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Breast Neuroendocrine Carcinoma

A neuroendocrine carcinoma arising from the breast. It is classified as small cell or large cell neuroendocrine carcinoma.


Locally Advanced HER2-Positive Breast Carcinoma

HER2-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Metastatic Hormone Receptor-Negative Breast Carcinoma

Hormone receptor-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Metastatic Breast Ductal Carcinoma

A ductal breast carcinoma that has spread from the original site of growth to another anatomic site.


Breast Carcinoma Metastatic in the Central Nervous System

A carcinoma that has spread to the central nervous system from its original site in the breast, through the hematogenous route.


Stage IIIA Breast Carcinoma

Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


small cell carcinoma of breast

A poorly differentiated neuroendocrine carcinoma that arises from the breast.  It is characterized by the presence of small neuroendocrine cells and high mitotic activity.


Locally Advanced Hormone Receptor-Positive Breast Carcinoma

Hormone receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


arenesulfonic acid

Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.


Acute prostatitis

An acute inflammatory process that affects the prostate gland.  It is caused by bacteria, most often Escherichia coli, Proteus mirabilis, Klebsiella, and Pseudomonas aeruginosa.


renal hypomagnesemia 4

Any primary hypomagnesemia in which the cause of the disease is a mutation in the EGF gene.


telencephalon astrocyte cell migration

biolink:BiologicalProcess biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

The orderly movement of an astrocyte cell through the telencephalon.


pyramidal neuron migration to cerebral cortex

The migration of a pyramidal neuron precursor from the ventricular zone to the correct layer of the cerebral cortex.


oligodendrocyte cell migration from the subpallium to the cortex

The directed movement of oligodendrocytes from the subpallium to the cerebral cortex during forebrain development.


telencephalon microglial cell migration

The orderly movement of microglial cells through the telencephalon.


telencephalon oligodendrocyte cell migration

The multiplication or reproduction of telencephalon oligodendrocyte cells, resulting in the expansion of a cell population.


Pathology Result

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon

The outcome of a pathologic examination.


High Grade Dysplasia

A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.


Large Cell Dysplasia

A premalignant neoplastic lesion of the liver.  It is characterized by the presence of hepatocytes with enlarged nuclei and cytoplasm, nuclear pleomorphism, multinucleation, and hyperchromasia.


Intestinal metaplasia of gastric mucosa

A morphologic finding indicating the replacement of part of the gastric mucosal epithelium with intestinal-type epithelium.  Using immunohistochemical staining, gastric intestinal metaplasia is classified as complete or incomplete.  Complete intestinal metaplasia is defined by the decreased expression of gastric mucins and expression of the intestinal mucin MUC2.  Incomplete intestinal metaplasia is defined by the co-expression of both gastric mucins and MUC2.


progressive transformation of germinal centers

Progressive transformation of germinal centers is a condition in which a lymph node becomes very enlarged (lymphadenopathy). Typically, only one lymph node is affected, though PTGC can involve multiple lymph nodes. Theneck is the most common location of affected lymph nodes, but PTGC may also affect lymph nodes in the groin and armpits. adults are more frequently affected than children, but children have a higher chance of developing PTGC multiple times (recurrence). PTGC is not considered a precancerous condition, though it has been associated with Hodgkin lymphoma.


Epithelial metaplasia

A morphologic finding that refers to the replacement of a group of one type of epithelial cells (e.g., glandular epithelial cells) to another type of epithelial cells (e.g., squamous epithelial cells).


Endometrial metaplasia

A morphologic finding indicating the alteration of the mature endometrial glandular epithelium to another that differs from that of normal endometrioid glands.


Deposit

Accumulation of extraneous inorganic matter in tissues or cavities.


cervical metaplasia

Metaplastic changes in the cervical glandular or squamous epithelium.


Histopathology Result

A finding resulting from the examination of a tissue sample under light or electron microscopy.


Low Phospho-AKT Immunohistochemical Expression


angiomatosis

A benign diffuse vascular proliferation usually occurring in young adults. It is characterized by the formation of capillary-sized and cavernous vascular spaces. Patients present with diffuse persistent swelling.


Intestinal Metaplasia of Columnar Epithelium

A morphologic finding indicating the replacement of part of the columnar epithelium by intestinal-type epithelium.


Transitional cell metaplasia

A morphologic finding that refers to the replacement of non-transitional epithelium (e.g., squamous epithelium) with transitional epithelium.


nephrogenic adenoma

So-called nephrogenic adenoma is a distinct metaplastic lesion of the urothelium characterized by aggregates of cuboidal or hobnail cells. These cells line thin papillary fronds on the surface or form tubular structures within the lamina propria.


Moderate Dysplasia

A morphologic finding indicating the presence of moderate cellular atypia associated with moderate architectural changes in a tissue sample.


Low Grade Oral Epithelial Dysplasia

Dysplasia in the oral cavity with low grade architectural and cytological epithelial changes.


Ischemic Necrosis

Loss of vascularization and tissue death caused by the disruption in the arterial access. Common causes include trauma due to accidents, insect or reptile bites, severe cold exposure or pathological conditions such as infarctions or blood dyscrasias.


Squamous Metaplasia Without Atypia

A morphologic finding indicating the transformation of glandular or transitional epithelial cells to squamous epithelial cells that lack atypical features.


Necrotic Change

A finding indicating the presence of cellular necrosis in a tissue specimen.


Cartilaginous Metaplasia of Malignant Cells Present


TP53 Loss of Nuclear Expression

An indication that expression of TP53 was not detected in the nuclei of cells in a sample.


Tuboendometrioid Metaplasia

Replacement of the endocervical-type epithelium of the cervix by benign tubal or endometrioid epithelium.


MSH6 Loss of Nuclear Expression

An indication that expression of MSH6 was not detected in the nuclei of cells in a sample.


MSH2 Loss of Nuclear Expression

An indication that expression of MSH2 was not detected in the nuclei of cells in a sample.


Smooth Muscle Metaplasia

A morphologic finding indicating the transformation of non-smooth muscle cells to smooth muscle cells.


Reticulin Fibrosis of the Bone Marrow

Increased reticular fiber deposition within bone marrow.


Mesenchymal Metaplasia of Malignant Cells Present


Neoplastic Cells with CD45 Dim-to-Negative Expression Present

An immunophenotypic finding indicating the presence of neoplastic cells with dim-to-negative CD45 expression.


Lymphoblasts with Surface Immunoglobulin Present

A microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of the immature lymphoid cells in a sample.


Squamous Dysplasia

A morphologic finding indicating the presence of dysplasia in the squamous epithelium of a tissue sample.


Loss or Reduction of Nuclear Histone H3 K28me3 Expression

A molecular genetic finding indicating the loss or reduction of nuclear histone H3 K28me3 (K27me3) expression in tumor cells.


Fallopian Tube Mucinous Metaplasia

Metaplastic mucinous changes in the fallopian tube epithelium. It may be seen in association with gynecological, appendiceal, or colonic mucinous tumors, or chronic inflammation.


PD-L1 Overexpression

An immunohistochemical test result that indicates overexpression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.


Small Cell Dysplasia

A premalignant neoplastic lesion of the liver.  It is characterized by the presence of hepatocytes with decreased cell volume, increased nuclear/cytoplasmic ratio, basophilia, mild nuclear pleomorphism, and hyperchromasia.


Renal Dysplasia Due to Fetal Exposure to ACE Inhibitor or ARB

Tubular dysgenesis resulting from maternal exposure to a class of drugs known as angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).


Apocrine metaplasia

A morphologic finding indicating the alteration of the glandular acinar epithelial cells to apocrine sweat gland cells.


Epiphysitis

Disorganization of the physeal chondrocytes with or without increased thickness of physis.


Congenital Dysplasia

Abnormal tissue formation due to abnormal cellular organization, which may result in a morphologic defect.


Squamous Metaplasia of Malignant Cells Present


Bronchial Epithelial Dysplasia

A non-invasive, precancerous lesion in the bronchial epithelium. Depending on the morphologic features it is classified as columnar cell dysplasia, basal cell dysplasia, squamous dysplasia, or bronchial epithelial dysplasia with transitional differentiation.


Massive Sinusoidal Histiocytic Infiltrate


Lung Squamous Dysplasia

A morphologic finding indicating the presence of dysplasia in the bronchial squamous epithelium. It is precursor of lung squamous cell carcinoma.


Dysplasia of larynx

Mild, moderate, or severe dysplasia of the squamous epithelium of the laryngeal mucosa.


Severe dysplasia

A morphologic finding indicating the presence of severe cellular atypia associated with severe architectural changes in a tissue sample.


Focal fibrosis

Localized formation of fibrous tissue.


advanced hepatic fibrosis

Septal or bridging fibrosis that results in the disruption of normal blood flow and liver function, and extends across hepatic lobules with significant porto-portal or porto-central bridging. Progression may lead to the formation of nodules that distort the liver architecture, which is termed cirrhosis.


Keratinizing Dysplasia

Epithelial dysplasia in which the dysplastic changes, although limited to the lower basal zone, are so severe that there is a high probability of progression to invasive carcinoma.


Spindle Cell Metaplasia of Malignant Cells Present


sinus histiocytosis with massive lymphadenopathy

A rare disorder of unknown etiology characterized by distention of the lymph node sinuses and sinusoidal histiocytic infiltration. The histiocytes characteristically contain ingested lymphocytes. Patients present with cervical lymphadenopathy, fever, leukocytosis, and hypergammaglobulinemia. It can affect extranodal sites, including skin, bones, and the respiratory tract. It usually regresses spontaneously.


Cervical Transitional Metaplasia

Cervical metaplasia in which the cervical squamous epithelium resembles benign urothelium as a result of a lack of cellular maturation.


Vaginal Transitional Cell Metaplasia

Vaginal metaplasia in which the vaginal surface squamous epithelium resembles benign transitional urothelium.


Oral Epithelial Dysplasia

A morphologic finding of dysplastic epithelial cells in the oral cavity.


Concentric Fibrosis of Intrahepatic Duct

A morphologic finding indicating the presence of fibrosis around an intrahepatic bile duct in the liver tissue.


Morular Metaplasia of the Endometrium

A morphologic finding indicating the replacement of part of the glandular endometrial epithelium by nodular structures that contain non-keratinizing squamous cells.


Renal Cell Dysplasia

A finding of congenital malformations in the kidney characterized by the presence of cysts of various sizes, primitive ducts, islands of metaplastic cartilage and undifferentiated mesenchyme, and the absence of cortico-medullary demarcation.


Morphologic Finding

A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.


Squamous Metaplasia of Bronchial Mucosa

Replacement of the bronchial glandular epithelial cells by squamous cells.


Columnar Metaplasia

A morphologic finding indicating the transformation of non-columnar epithelial cells into columnar cells.


Hurthle cell metaplasia of thyroid gland

A morphologic finding indicating transformation of follicular cells to large cells with abundant eosinophilic and granular cytoplasm (Hurthle cells) in the thyroid gland.


Loss of Immunohistochemical Expression of Succinate Dehydrogenase (SDH) B

An immunohistochemical test result indicating the loss of expression of succinate dehydrogenase (SDH) B in the neoplastic cells of a tumor sample.


Apocrine metaplasia of breast

A morphologic finding indicating the transformation of the epithelial cells in a breast tissue sample to cells with abundant eosinophilic cytoplasm.


Non-Keratinizing Dysplasia

Epithelial dysplasia in which there is continuum from mild dysplasia to moderate dysplasia to severe dysplasia before the development of invasive carcinoma.


Glandular metaplasia

A morphologic finding indicating the alteration of the squamous or transitional epithelial cells to glandular cells.


EPCAM Loss of Nuclear Expression

An indication that expression of EPCAM was not detected in the nuclei of cells in a sample.